Sysmex Corporation (TYO:6869)

Japan flag Japan · Delayed Price · Currency is JPY
1,994.00
-62.50 (-3.04%)
Aug 14, 2025, 3:30 PM JST
-24.97%
Market Cap 1.24T
Revenue (ttm) 502.43B
Net Income (ttm) 47.19B
Shares Out 623.61M
EPS (ttm) 75.66
PE Ratio 26.35
Forward PE 20.54
Dividend 36.00 (1.75%)
Ex-Dividend Date Sep 29, 2025
Volume 4,188,100
Average Volume 2,207,375
Open 2,036.00
Previous Close 2,056.50
Day's Range 1,982.00 - 2,037.50
52-Week Range 1,981.50 - 3,236.00
Beta 0.82
RSI 21.38
Earnings Date Aug 6, 2025

About Sysmex

Sysmex Corporation engages in the development, manufacture, and sale of diagnostic instruments, reagents, and related software. It offers non-clinical blood testing and cell analysis for hematology, such as XN-V series, a software for laboratory animal corresponding to XN series fully automated hematology analyzers; XN-Series, a fully automated flagship hematology analyzers; and Automated hematology analyzer ProCyte Dx for Research applications, a housed in a compact body that simultaneously measures five types of leukocytes and reticulocyte co... [Read more]

Sector Healthcare
Founded 1968
Employees 10,533
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 6869
Full Company Profile

Financial Performance

In 2024, Sysmex's revenue was 508.64 billion, an increase of 10.21% compared to the previous year's 461.51 billion. Earnings were 53.67 billion, an increase of 8.12%.

Financial Statements

News

Sysmex reports FQ1 results

Sysmex (SSMXY) reports FQ1 results: Net sales down 5.6%, operating profit drops 36.5%, and attributable profit declines 58.7%.

8 days ago - Seeking Alpha

Sysmex reports 9M results

6 months ago - Seeking Alpha

Sysmex GAAP EPS of ¥41.70, revenue of ¥242.48B

Sysmex (SSMXY) reports a strong 1H performance with GAAP EPS of ¥41.70 and revenue of ¥242.48B, an impressive 14.0% increase year-over-year.

9 months ago - Seeking Alpha